Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --

3Q09 Corporate Highlights:

  • Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd.
  • Made significant progress in commercial readiness activities
  • Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations
  • Appointed Bradford S. Goodwin to board as director and Audit Committee chairman

Upcoming 2009 Milestones:

  • FDA PDUFA date November 16, 2009 for Qutenza NDA to manage pain associated with PHN

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009.

During the third quarter of 2009, NeurogesX prioritized three key initiatives: 1) supporting the ongoing U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Qutenza for postherpetic neuralgia (PHN), 2) preparing for potential commercial launch of Qutenza in the United States pending FDA approval and 3) supporting Astellas Pharma Europe Ltd., the commercial partner for Qutenza in Europe, the Middle East and Africa, in their efforts to prepare for a Qutenza launch in the European Union in 2010.

In the U.S., NeurogesX is currently awaiting a decision from FDA regarding its NDA for Qutenza to manage pain associated with PHN. The agency has assigned an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009. In preparation for the possible approval and subsequent planned launch of Qutenza in the United States in the first half of 2010, the Company continued to make significant advances in a number of key product laun
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... 25 BN,ImmunoTherapeutics, Inc. announced today that the ... licensed from the National Institutes of,Health (NIH) is ... the,excellent safety and efficacy results previously reported, will ... on February 26-28, 2009 in,Orlando, Florida. , ...
... 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ... researching,developing, manufacturing and marketing biopharmaceutical products, today,announced that ... quarter and,full year ended December 31, 2008 after ... , Following the earnings ...
... Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled ... patch Phase III program. The program consists of ... Cerimon,s diclofenac patch. The studies will assess the ... placebo for the treatment of acute pain caused by ...
Cached Biology Technology:BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 33SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
(Date:9/2/2014)... September 2, 2014 In a new study that ... the Florida campus of The Scripps Research Institute (TSRI) ... into unique manufacturing sites for molecules that can treat ... cell as a reaction vessel and a disease-causing defect ... diseased cell," said TSRI Professor Matthew Disney.,"Because the treatment ...
(Date:9/2/2014)... research suggests that professional baseball pitchers with poor core stability ... a single season because of injury than are pitchers who ... pelvis. , In the study, 347 pitchers were assessed for ... their pelvis as they raised a leg to step up ... least 30 days cumulative, not consecutive during the ...
(Date:9/2/2014)... think losing weight is enough to prevent Type 2 diabetes, ... September 2014 issue of The FASEB Journal ... develop Type 2 diabetes. This study compared genetically identical twins-one ... meal, the circulating metabolites, including those related to Type 2 ... These findings suggest that the onset of this type ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2
... and smoke forecasting models are useful tools to help ... in areas at risk from forest fire smoke, according ... Brauer shares his insight into the health impacts ... them today at the American Association for the Advancement ...
... This press release is available in French . ... are lots of new ideas out there for giving you extra ... good ideas may never make it to market. Researchers ... a way to enrich milk with docosahexaeonic acid (DHA)an essential nutrient ...
... An international team from the Nippon Foundation-University of British ... of life in the world,s oceans, allowing scientists and ... the state of life in the oceans of ... factors impacting our oceans climate change, human activity ...
Cached Biology News:As climate change increases forest fires, smoke forecasting could help protect public health 2Window into world's future oceans unveiled by NF-UBC Nereus team 2Window into world's future oceans unveiled by NF-UBC Nereus team 3
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 ... from human DNA fragmentation factor (DFF). The sequence of ... - P - K - S - V - K ... - S - P - R - K(18). ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... High Throughput Processing of Microarrays Using the ... Frame multiple slide plate is designed to ... corresponding multi-well incubation chambers in a microplate ... The footprint dimensions meet the standards recommended ...
fully automated system for the processing of microarrays on microscope slides...
Biology Products: